Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
ObjectivesTo evaluate the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy for resectable gastric cancer compared to those of neoadjuvant chemotherapy.MethodsA systematic review and meta-analysis of the randomized controlled trials (RCTs) of neoadjuvant chemoradiotherapy versu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.927119/full |
| _version_ | 1818537052871852032 |
|---|---|
| author | Jiuzhou Chen Jiuzhou Chen Yaru Guo Yaru Guo Miao Fang Miao Fang Yan Yuan Yan Yuan Youqi Zhu Youqi Zhu Yong Xin Yong Xin Longzhen Zhang Longzhen Zhang |
| author_facet | Jiuzhou Chen Jiuzhou Chen Yaru Guo Yaru Guo Miao Fang Miao Fang Yan Yuan Yan Yuan Youqi Zhu Youqi Zhu Yong Xin Yong Xin Longzhen Zhang Longzhen Zhang |
| author_sort | Jiuzhou Chen |
| collection | DOAJ |
| description | ObjectivesTo evaluate the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy for resectable gastric cancer compared to those of neoadjuvant chemotherapy.MethodsA systematic review and meta-analysis of the randomized controlled trials (RCTs) of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy were performed in patients with resectable gastric cancer.ResultsSeven RCTs were included (601 patients; 302 in the neoadjuvant chemoradiotherapy group and 299 in the neoadjuvant chemotherapy group). The neoadjuvant chemoradiotherapy group had an increased number of patients with a complete response [odds ratio (OR) = 3.79, 95% confidence interval (CI): 1.68–8.54, p = 0.001] and improved objective response rate (OR = 2.78, 95% CI: 1.69–4.57, p < 0.0001), 1-year (OR = 3.51, 95% CI: 1.40–8.81, p = 0.007) and 3-year (OR = 2.14, 95% CI: 1.30–3.50, p = 0.003) survival rates, R0 resection rate (OR = 2.21, 95% CI: 1.39–3.50, p = 0.0008), and complete pathologic response (OR = 4.39, 95% CI: 1.59–12.14, p = 0.004). Regarding the incidence of adverse effects after neoadjuvant therapy, only the occurrence rate of gastrointestinal reaction in the neoadjuvant chemoradiotherapy group was higher than that in the neoadjuvant chemotherapy group (OR = 1.76, 95% CI: 1.09–2.85, p = 0.02), and there was no significant difference in other adverse effects. There was no difference in the incidence of postoperative complications between the two groups.ConclusionNeoadjuvant chemoradiotherapy for resectable gastric cancer has several advantages in terms of efficacy and safety compared to neoadjuvant chemotherapy. Therefore, neoadjuvant chemoradiotherapy has great potential as an effective therapy for resectable gastric cancers.Systematic Review Registrationhttps://inplasy.com/inplasy-2022-3-0164, registration number INPLASY202230164. |
| first_indexed | 2024-12-11T18:45:47Z |
| format | Article |
| id | doaj.art-5c028f781b614c51a172082c7ccd92f5 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T18:45:47Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-5c028f781b614c51a172082c7ccd92f52022-12-22T00:54:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.927119927119Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysisJiuzhou Chen0Jiuzhou Chen1Yaru Guo2Yaru Guo3Miao Fang4Miao Fang5Yan Yuan6Yan Yuan7Youqi Zhu8Youqi Zhu9Yong Xin10Yong Xin11Longzhen Zhang12Longzhen Zhang13Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Cancer Institute, Xuzhou Medical University, Jiangsu, ChinaDepartment of Radiation, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Cancer Institute, Xuzhou Medical University, Jiangsu, ChinaDepartment of Radiation, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Cancer Institute, Xuzhou Medical University, Jiangsu, ChinaDepartment of Radiation, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Cancer Institute, Xuzhou Medical University, Jiangsu, ChinaDepartment of Radiation, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Cancer Institute, Xuzhou Medical University, Jiangsu, ChinaDepartment of Radiation, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Cancer Institute, Xuzhou Medical University, Jiangsu, ChinaDepartment of Radiation, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Cancer Institute, Xuzhou Medical University, Jiangsu, ChinaObjectivesTo evaluate the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy for resectable gastric cancer compared to those of neoadjuvant chemotherapy.MethodsA systematic review and meta-analysis of the randomized controlled trials (RCTs) of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy were performed in patients with resectable gastric cancer.ResultsSeven RCTs were included (601 patients; 302 in the neoadjuvant chemoradiotherapy group and 299 in the neoadjuvant chemotherapy group). The neoadjuvant chemoradiotherapy group had an increased number of patients with a complete response [odds ratio (OR) = 3.79, 95% confidence interval (CI): 1.68–8.54, p = 0.001] and improved objective response rate (OR = 2.78, 95% CI: 1.69–4.57, p < 0.0001), 1-year (OR = 3.51, 95% CI: 1.40–8.81, p = 0.007) and 3-year (OR = 2.14, 95% CI: 1.30–3.50, p = 0.003) survival rates, R0 resection rate (OR = 2.21, 95% CI: 1.39–3.50, p = 0.0008), and complete pathologic response (OR = 4.39, 95% CI: 1.59–12.14, p = 0.004). Regarding the incidence of adverse effects after neoadjuvant therapy, only the occurrence rate of gastrointestinal reaction in the neoadjuvant chemoradiotherapy group was higher than that in the neoadjuvant chemotherapy group (OR = 1.76, 95% CI: 1.09–2.85, p = 0.02), and there was no significant difference in other adverse effects. There was no difference in the incidence of postoperative complications between the two groups.ConclusionNeoadjuvant chemoradiotherapy for resectable gastric cancer has several advantages in terms of efficacy and safety compared to neoadjuvant chemotherapy. Therefore, neoadjuvant chemoradiotherapy has great potential as an effective therapy for resectable gastric cancers.Systematic Review Registrationhttps://inplasy.com/inplasy-2022-3-0164, registration number INPLASY202230164.https://www.frontiersin.org/articles/10.3389/fonc.2022.927119/fullresectable gastric cancergastrointestinal cancersneoadjuvant chemoradiotherapyneoadjuvant chemotherapymeta-analysis |
| spellingShingle | Jiuzhou Chen Jiuzhou Chen Yaru Guo Yaru Guo Miao Fang Miao Fang Yan Yuan Yan Yuan Youqi Zhu Youqi Zhu Yong Xin Yong Xin Longzhen Zhang Longzhen Zhang Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis Frontiers in Oncology resectable gastric cancer gastrointestinal cancers neoadjuvant chemoradiotherapy neoadjuvant chemotherapy meta-analysis |
| title | Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis |
| title_full | Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis |
| title_fullStr | Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis |
| title_full_unstemmed | Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis |
| title_short | Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis |
| title_sort | neoadjuvant chemoradiotherapy for resectable gastric cancer a meta analysis |
| topic | resectable gastric cancer gastrointestinal cancers neoadjuvant chemoradiotherapy neoadjuvant chemotherapy meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.927119/full |
| work_keys_str_mv | AT jiuzhouchen neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT jiuzhouchen neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT yaruguo neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT yaruguo neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT miaofang neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT miaofang neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT yanyuan neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT yanyuan neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT youqizhu neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT youqizhu neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT yongxin neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT yongxin neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT longzhenzhang neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis AT longzhenzhang neoadjuvantchemoradiotherapyforresectablegastriccancerametaanalysis |